voriconazole (Vfend)

DRUG3 trials

Sponsors

Pfizer

Conditions

CandidemiaCandidiasisNon-Melanoma Skin CarcinomaPossible Fungal Infection

Phase 2

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

CompletedNCT00739934

PfizerCandidemia, Candidiasis

Start: 2008-12-31End: 2009-10-31Updated: 2011-01-28

Phase 3

Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

CompletedNCT00150345

PfizerPossible Fungal Infection

Start: 2005-01-31End: 2009-04-30Updated: 2012-01-19

Unknown Phase

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

CompletedNCT01480219

PfizerNon-Melanoma Skin Carcinoma

Start: 2011-08-31End: 2012-03-31Updated: 2013-03-11